

Title: COVID-19 Public Health Emergency:
Telehealth Waiver for CDTM Consultations

Policy No. I.D.29

Issued: 08-18-2021

-
1. The Board's rule for collaborative drug therapy management (CDTM) in Section 523 requires the pharmacist to be physically present to provide pharmacist care to a patient, and to be available through direct telecommunication for consultation. The relevant subsection of the CDTM rule is replicated here:

§523. Collaborative Drug Therapy Management

D. Standards of Practice

1. Authority, Responsibility, and Limitations of Collaborative Drug Therapy Management

a. ...

b. A pharmacist engaged in collaborative drug therapy management shall:

i. - ii. ...

iii. be geographically located to be physically present to provide pharmacist care to a patient subject to collaborative drug therapy management;

iv. ...

v. be available through direct telecommunication for consultation, assistance, and direction.

D.1.c. - D.5.b. ...

2. The Board is currently in the process of revising the CDTM rule, and the current board-approved [Draft #1](#) will result in the removal of the requirement for physical presence of the pharmacist to provide care to a patient and will retain the requirement for availability for direct communication for consultation, assistance, and direction.
3. Given the current conditions during the COVID-19 public health emergency, including limitations on patient access to care, the Board has determined it reasonable to waive the requirement for the physical presence of the pharmacist to provide CDTM consultations and permit the pharmacist to use appropriate HIPAA-compliant telehealth services to conduct CDTM consultations with patients.